Omnicals Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 13-12-2024
- Paid Up Capital ₹ 2.08 M
as on 13-12-2024
- Company Age 7 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -19.01%
(FY 2022)
- Profit 7.10%
(FY 2022)
- Ebitda 15.99%
(FY 2022)
- Net Worth 78.87%
(FY 2022)
- Total Assets 15.41%
(FY 2022)
About Omnicals Pharma
The Company is engaged in the Business Outsourcing Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 2.08 M, as per Ministry of Corporate Affairs (MCA) records.
Nidhi Pathak, Anurag Pathak, Rohit Negi, and One other member serve as directors at the Company.
- CIN/LLPIN
U33309MH2017PTC294976
- Company No.
294976
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 May 2017
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Omnicals Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anurag Pathak  | Managing Director | 08-Aug-2017 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Nidhi Pathak | Director | 03-May-2023 | Current |
| Rohit Negi | Director | 17-May-2017 | Current |
| Anil Fokmare | Director | 15-Dec-2022 | Current |
Financial Performance of Omnicals Pharma.
Omnicals Pharma Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 19.01% decrease. The company also saw a slight improvement in profitability, with a 7.1% increase in profit. The company's net worth Soared by an impressive increase of 78.87%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Omnicals Pharma?
In 2023, Omnicals Pharma had a promoter holding of 89.55% and a public holding of 10.45%. The company had 3 Associate Companies. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Finoso Life Sciences Private LimitedActive 5 years 2 monthsNidhi Pathak, Anurag Pathak and 1 more are mutual person
- Omnikam Private LimitedActive 3 years 7 months
Anurag Pathak, Rohit Negi and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Omnicals Pharma?
Omnicals Pharma has a workforce of 14 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Omnicals Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Omnicals Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
